-+ 0.00%
-+ 0.00%
-+ 0.00%
IRulya Therapeutics Presents LAM-001 Phase 2a Data in Pulmonary Hypertension
Share
Listen to the news
IRulya Therapeutics Presents LAM-001 Phase 2a Data in Pulmonary Hypertension
  • IRulya Therapeutics expects Phase 2 data for inhaled rapamycin LAM-001 in bronchiolitis obliterans syndrome in the first quarter of 2027.
  • The fully enrolled, 19-patient BOS trial remains blinded, with dosing continuing.
  • An ongoing 75-patient Phase 2b trial in pulmonary hypertension associated with interstitial lung disease has data anticipated in the first quarter of 2028.
  • A Phase 2 sarcoidosis-associated pulmonary hypertension trial is expected to start in the fourth quarter of 2026; data are anticipated in late 2028.
  • Financing included an oversubscribed $115 million upfront round in May 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IRulya Therapeutics Inc. published the original content used to generate this news brief on November 17, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending